Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-71

Hey mate.

The reason I can comment with a level of authority on IMU is because I have researched their clinical programs and associated fields for a long time.

It would take me a fair amount of time to understand the clinical and commercial context of PAR to comment critically with a reasonable level of accuracy.

I am not really aware of this forum or company, but if there is an independent analysts like myself who comments on PAR that would be willing to critically review RAC with outstanding depth, I will do the same for PAR. I think that this would benefit both companies, as we both likely have strengths the other does not, which strengthens the understanding of the IP.

If someone fits the description and is keen, let me know.